Additionally, regorafenib targets the RET-Src signaling axis to inhibit JAK1/2-STAT1 and MAPK signaling and concurrently inhibits PD-L1 expression, suggesting inhibition of RET-Src axis may impact immune response to tumor cells in vivo (243). Here, RET is linked to neoplasm.